Hangzhou Biotest Stock Hits Day Low of CNY 37.41 Amid Price Pressure

Hangzhou Biotest Biotech Co., Ltd. experienced a significant decline today, with the stock dropping by 6.19% and reaching an intraday low of CNY 37.41. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 2.04% on the same day. Over the past week, Hangzhou Biotest has seen a more pronounced downturn, with a decline of 11.23%. Year-to-date, the stock has remained relatively stable, showing a slight decrease of 0.16%. However, the one-year performance reflects a more concerning trend, with a drop of 14.37%, while the Shanghai Composite has gained 20.36% during the same period. Financial metrics indicate challenges for the company, including a significant decrease in net sales by 13.84% and a net profit of CNY 9.86 million, which has fallen by 42.12%. The company's debt-equity ratio stands at a notably high -65.15%, and its return on equity is just 1.20%. These figures highlight the ongoing difficulties faced by Hangzhou Biotest in the competitive pharmaceuticals and biotechnology sector.